Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Febrile Neutropenia Market Size Outlook: How Quickly Will Revenue Expand Through 2030?
The febrile neutropenia market has seen robust expansion over recent years. Its valuation is predicted to rise from $11.28 billion in 2025 to $11.99 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.3%. This historical growth can be linked to an increase in cancer chemotherapy utilization, a surge in hospital admissions, the accessibility of a wide range of broad-spectrum antibiotics, heightened awareness about infections, and the establishment of more oncology centers.
The febrile neutropenia market size is anticipated to undergo significant expansion in the coming years, projected to swell to $15.19 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.1%. This growth during the forecast period can be primarily ascribed to advancements in targeted antimicrobial therapy, an increasing oncology patient population, enhanced early infection detection, the growing application of G-CSFs, and the widening reach of precision oncology care. Noteworthy trends for the forecast period include an escalating incidence of chemotherapy-induced neutropenia, a rise in empirical antibiotic therapy utilization, the increasing adoption of supportive care treatments, an expansion of hospital-based infection management practices, and improvements in diagnostic and monitoring technologies.
Get A Free Sample Report With In-Depth Market Insights:
Febrile Neutropenia Market Expansion Drivers: What’s Shaping Future Growth?
The expanding occurrence of cancer is projected to advance the growth of the febrile neutropenia market. Cancer is characterized as a complex group of illnesses where abnormal cells proliferate uncontrollably, potentially invading adjacent tissues and metastasizing throughout the body. The escalating incidence of cancer is attributable to factors like an aging population, exposure to environmental and occupational hazards, genetic predispositions, and hormonal and reproductive elements. Febrile neutropenia offers vital support to cancer patients by highlighting the heightened risk of infections during chemotherapy, thereby promoting prompt intervention and targeted therapies to prevent severe, life-threatening complications, which in turn improves patient outcomes and facilitates the continuous delivery of cancer treatment. For instance, in 2024, the Canadian Cancer Society, a Canada-based national cancer charity, noted that 32,100 people in Canada were diagnosed with lung cancer, accounting for 23.5% of all cancer-related deaths. It was also observed that lung cancer cases among females rose from 15,800 cases in 2023 to 17,300 cases in 2024. As a result, the increasing prevalence of cancer is a key driver for the growth of the febrile neutropenia market.
Febrile Neutropenia Market Segment Performance And Emerging Opportunities
The febrile neutropenia market covered in this report is segmented –
1) By Treatment: Empirical Antibiotic Therapy, Targeted Antibiotic Therapy, Supportive Care
2) By Risk Factors: Chemotherapy-Induced Neutropenia, Transplant-Related Neutropenia, Genetic Disorders
3) By Etiology: Gram-Negative Bacteria, Gram-Positive Bacteria, Fungal Infections, Viral Infections
4) By Diagnostic Methods: Blood Cultures, Imaging Tests, Bone Marrow Aspiration
Subsegments:
1) By Empirical Antibiotic Therapy: Broad-Spectrum Beta-Lactams, Glycopeptides, Carbapenems
2) By Targeted Antibiotic Therapy: Antifungal Therapy, Antiviral Therapy, Gram-Positive Bacterial Therapy, Gram-Negative Bacterial Therapy
3) By Supportive Care: Granulocyte Colony-Stimulating Factors (G-CSFs), Intravenous Fluids, Antipyretics And Pain Management
Febrile Neutropenia Market Industry Trends Fueling Future Revenue Growth
Leading firms within the febrile neutropenia sector are prioritizing the creation of sophisticated biosimilar medications, including long-acting granulocyte-colony stimulating factor (G-CSF) fusion proteins, aiming for a competitive edge. Such fusion G-CSFs consist of recombinant proteins that connect G-CSF with an Fc fragment, allowing for prolonged neutrophil stimulation throughout a chemotherapy cycle. As an illustration, in November 2024, Evive Biotech, a biopharmaceutical firm headquartered in Singapore, launched in Germany a non-pegylated, long-acting G-CSF intended for chemotherapy-induced neutropenia. This product provides an extended half-life through an IgG2-Fc fusion and utilizes mammalian cell expression to achieve human-like glycosylation. While these next-generation and biosimilar G-CSFs enhance patient accessibility and decrease the required dosing frequency, they are confronted with intricate regulatory challenges and possible immunogenicity issues.
Febrile Neutropenia Market Key Players: Which Companies Lead Industry Competition?
Major companies operating in the febrile neutropenia market are Pfizer Inc., Sanofi S.A., Amgen Inc., Teva Pharmaceutical Industries Ltd., Fresenius Kabi, Aurobindo Pharma Ltd., Lupin Limited, Hospira Inc., Coherus BioSciences Inc., Gennova Biopharmaceuticals Limited, Dr Reddy’s Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Novartis AG, Merck & Co. Inc., AstraZeneca PLC, Bayer AG, Cipla Ltd., Zydus Cadila, Celltrion Inc., Samsung Bioepis Co. Ltd.
View The Full Febrile Neutropenia Market Report:
Febrile Neutropenia Market Regional Breakdown: Where Is Demand Concentrated?
North America was the largest region in the febrile neutropenia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the febrile neutropenia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model









